A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis.
Ohashi
Yuichi
Y
Department of Ophthalmology, University of Ehime School of Medicine, Shizukawa, Toon City Ehime, 7910295, Japan. ohashi@m.ehime-u.ac.jp
Ebihara
Nobuyuki
N
Fujishima
Hiroshi
H
Fukushima
Atsuki
A
Kumagai
Naoki
N
Nakagawa
Yayoi
Y
Namba
Kenichi
K
Okamoto
Shigeki
S
Shoji
Jun
J
Takamura
Etsuko
E
Hayashi
Kunihiko
K
D000293:Adolescent; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015994:Incidence; D008297:Male; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000009:adverse effects; D018434:Sickness Impact Profile; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D009883:Ophthalmic Solutions; D016559:Tacrolimus